Previously, Puri et . 1991. Cancer Res. 51:3011-3017) have demonstrated that murine sarcoma and colon adenocarcinoma cells express high affinity interleukin4 receptors (IL-4R) which are internalized after binding to a chimeric ligand consisting of IL-4 and Pseudomonas exotoxin. In the present study, we have tested primary cultures of human renal cell carcinoma (RCC) cells, generated from tumor specimens obtained after nephrectomy, for the expression of IL4R and their modulation by IL4. By using iodinated IL4 in a receptor binding assay, we observed that renal cell carcinoma cells expressed a single class of high affinity IL4R ranging from 1,425±207 (mean±SEM) to 3,831±299 (mean±SEM) IL4R molecules/cell with a Kd ranging from 112±11 pM to 283±71 pM. Northern blot analysis for IL4R gene expression, performed with a cDNA probe to IL4R, revealed that all RCC cells exhibited a single mRNA species of 4 kb. IL4 downregulated the surface expression of IL4R on one RCC tumor cell line. The function of IL-4R expression on RCC tumor cells was further determined by investigating the effect of IL4 on tumor cell growth in vitro and comparing it with IL-4 effect on growth of normal fibroblast and endothelial cell lines. Tumor cell growth, as measured by [3H]thymidine incorporation, was inhibited by IL4 from 20 to 68% in a dose-dependent manner. A neutralizing antibody to human IL-4 was able to reverse the growth inhibitory effect of IL4. Normal human fibroblast and endothelial cell lines also expressed high affinity IL4R, however, IL4 did not inhibit their growth in vitro. In fact, IL-4 caused modest stimulation of their growth. Taken together, our findings can help develop strategies for the treatment of RCC in which IL-4R may be used as a target for IL4 itself, for IL4 toxin therapy or, alternatively, in gene therapy. (J. Clin. Invest. 1993. 91:88-93.) Key words: IL4 receptors on renal cell carcinoma * modulation of IL4 receptors * tumor cell growth inhibition experiments. The human Burkitt lymphoma-B cell lines, Molt-4 and Daudi, were kindly provided by Dr. J. A. Hank (University ofWisconsin, Madison, WI). Normal human skin fibroblast cell lines (39-Sk and 969-Sk) and human umbilical vein endothelial (HUVE) cells were obtained from American Type Culture Collection, Rockville, MD.
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Receivedfor publication 13 March 1992 and in revisedform 31 July 1992. terized on the basis of its effects on activated B cells (4), IL-4 has since been shown to have a variety of effects on different cell types. It has been shown to promote survival, growth, and differentiation of both B and T lymphocytes (5) (6) (7) (8) , mast cells (9, 10) , and endothelial cells (1 1). IL-4 affects macrophages by inhibiting the production of tumor necrosis factor, IL-1, and IL-6 (12, 13) . More recently, has also been shown to have antitumor effects in murine models of malignancy (14) (15) (16) and to inhibit proliferation of human tumor cell growth in vitro (17, 18) . Although others have shown that the effect ofIL-4 on immune cells are mediated through IL-4 receptor (IL-4R) (19, 20) , the expression of functional IL-4R on nonlymphoid human tumors has not been described. In a recent study, Puri et al. (21) demonstrated the expression of high affinity IL-4R on murine sarcoma and adenocarcinoma tumor cells. These receptors were capable of internalizing IL-4 after binding to its receptor. In the current study, we have examined primary cultures of human renal carcinoma cells and normal fibroblasts and endothelial cells for the expression of IL-4R. Our results indicate that human renal cell carcinoma (RCC)' cells express mRNA for IL-4R and a single class of high affinity IL-4R on the cell surface. Furthermore, IL-4 caused a decrease in the density of IL-4R and tumor cell proliferation suggesting that antitumor effects may be mediated through downregulation of its own receptors. High affinity IL-4Rs were also expressed on normal human fibroblast and endothelial cell lines, however, IL-4 did not inhibit, but caused a modest stimulation of their growth in vitro. Radioreceptor binding assay. Recombinant human IL-4 was enzymatically labeled with '25I (Amersham Corp., Arlington Heights, IL) by the enzymobead method according to manufacturer's instructions (Bio-Rad Laboratories, Richmond, CA). The specific activity of the radiolabeled IL-4 was determined by competition for binding sites of labeled IL-4 with unlabeled IL-4 using the IL-4R-positive gibbon lymphoma cell line, MLA 144. The specific activity of '25I-IL-4 was estimated to range from 6 X I09 to 5 X 1010 cpm/mg protein.
Methods
For IL-4R assays, equilibrium binding studies were performed by the method previously described (21, 22) . Briefly, 2.5 x 106 RCC cells in 126 Ml binding buffer (RPMI 1640 containing 0.2% human serum albumin) were incubated with various concentrations of '25I-IL-4 at 4°C in polypropylene tubes in a shaking water bath. For each concentration of '25I-IL-4, nonspecific binding was determined by including 100-200 molar excess of unlabeled IL4 in duplicate tubes. Cell-bound '251I-IL-4 was separated by centrifugation through a cushion of phthalate oils and counted in a gamma counter. The number of receptors and binding affinities were determined by Scatchard plot analysis ofthe data (23) .
For regulation experiments, PM-RCC tumor cells were cultured with or without IL-4 (20 ng/ml) for 72 h at 37°C. Cells were then harvested and IL-4R determined.
Northern blot analysis. Adherent tumor cells were harvested from tissue culture flasks by brief exposure to versene (Whittaker Bioproducts, Walkersville, MD). After several washes, total RNA was extracted with RNAzol (Cinna/Biotecx Laboratories, Friendswood, TX) in a one-step procedure according to the manufacturer's instructions. 10 Mig of total RNA were electrophoresed through 1% agarose/formaldehyde denaturing gel and transferred to a nylon membrane (S and S Nytran; Schleicher and Schuell, Keene, NH) by capillary action (24) . The nucleic acid was bound to the membrane by ultraviolet cross-linking (Stratagene Inc., La Jolla, CA). After a 12-h prehybridization at 42°C, the immobilized RNA was allowed to hybridize at 42°C for 12 h with a 32P-labeled human IL-4R cDNA probe (32P-deoxycytidine was obtained from ICN ImmunoBiologicals, Costa Mesa, CA). Filters were exposed to autoradiographic film for 3-10 d.
Assayfor tumor cell growth. Tumor or normal cells were harvested from tissue culture flasks with versene or trypsin and resuspended to a concentration of 5 x 104 cells/ml in complete medium. 100 M1 of this suspension were then plated in quadruplicates in a 96-well flat-bottomed microtiter plate and supplemented with 0-1,000 ng/ml 
Results
Cell surface expression ofIL-4R. To investigate the expression and binding affinity of IL-4R, we incubated RCC tumor cells with increasing concentrations of 125I-IL-4 at 4°C for 2 h. Rep- resentative results from two RCC lines (WS-RCC and GW-RCC) are shown in Fig. 1 . RCC tumor cells bound IL-4 in a concentration dependent manner ( Fig. 1 A) . Scatchard plot analysis ofthe binding data suggested that a single class of high affinity IL-4R were expressed on GW-RCC (Kd = 112+11, n = 3), WS-RCC (Kd = 130±0, n = 2) ( Fig. 1 B) and PM-RCC tumor cells (Kd = 283±71 pM, mean±SEM, n = 4) (not shown). In multiple experiments, the number of IL-4 molecules bound/cell on the PM-RCC tumor cells was 3,831±299 (mean±SEM, n = 4), on WS-RCC 2,269±132 (n = 2), and on GW-RCC tumor cells was 1,425±207 (n = 3). Other RCC tumor cells also expressed similar number of IL-4R (data not (Table I) . IL-4R gene expression. Northern blot analysis of IL-4R gene expression was performed on RCC tumor cells. RNA from CTLL-2 cells, a mouse cytotoxic T cell line, was included as a negative control while RNA from CTLL-2 cells transfected with the human IL-4R cDNA (CTLL-T22-8) (20) was used as a positive control. RNA from CTLL-2 cells did not hybridize with the hIL-4R cDNA probe ( Fig. 2 A, lane 1) while RNA from the IL-4R transfected cell line did (Fig. 2 , lane 2). All tested RCC tumor cell lines expressed a high density of single species of mRNA (size: 4.0 kb) for hIL-4R ( Fig. 2 A, lanes 3-5).
We also examined the mRNA expression for IL-4R on Daudi and Molt-4 cells. As depicted in Fig. 2 B , only CTLL-2-T22-8 cells (lane 1) and Daudi cells (lane 2) expressed the mRNA for IL-4R, however, we did not observe any hybridization with Molt-4 RNA (Fig. 2 B, lane 3) .
Effect ofIL-4 on tumor cell growth. To determine the functional significance of the expression of high affinity IL-4R on RCC tumor cells, we tested the effect of IL-4 on the growth of these cells in tissue culture. We found that IL-4 caused a direct antiproliferative effect of varying degree on RCC tumor cells isolated from several patients. This tumor growth inhibition mediated by IL-4 was dose dependent ( Fig. 3 A) . Maximum inhibition of PM-RCC and GW-RCC tumor cell growth (-50%) was observed at IL-4 concentration of 10-100 ng/ml ( Fig. 3 A) , while no further inhibition was observed at higher concentrations (100-1,000 ng/ml) ( Fig. 4) . IL-4-mediated growth inhibition was reproducible and observed in other RCC tumor lines. IL-4 at 10 ng/ml inhibited the growth ofRG-RCC, TR-RCC, and SJ-RCC, by 68, 31, and 39%, respectively. Although Daudi cells have been shown to express IL-4R (19, 25) , the growth inhibitory effect of IL-4 was not observed in these cells ( Fig. 3 A) indicating that the IL-4 effect is cell type specific.
The level of inhibition of RCC tumor cell growth as determined by cell counts at the end of 7-d culture with IL-4 was comparable to that observed with [3H]thymidine uptake. However, cell viability (as determined by trypan blue exclusion) was 100% in both IL-4-treated and untreated groups (data not shown). These data indicate that IL-4 caused cytostatic rather than cytotoxic effects on RCC tumor cells.
To establish that the observed growth inhibitory effects were mediated directly by IL-4, we investigated the effect of a neutralizing antibody directed against human IL-4 on RCC tumor cell proliferation. We found that anti-IL-4 antibody reversed the growth inhibition caused by IL-4 in a concentrationdependent manner (Fig. 3 B) . At 10 ,ug/ml, the anti-IL-4 antibody significantly neutralized the antiproliferative effects of IL-4 (P < 0.03), however, complete neutralization was not observed. Thus our data corroborate previous findings (18) and further suggest that the antiproliferative effects of IL-4 are mediated through its receptors. Effect ofIL-4 on normal cell lines. To understand the significance of growth inhibitory effects of IL-4 on RCC tumor cells, we tested the effects of IL-4 on the growth of normal cell lines. Two normal human skin fibroblasts cell lines (969-Sk and 39-Sk) were used in a 4-d proliferation assay and their proliferation was compared to that of RCC tumor cells. IL-4 caused modest stimulation of growth of normal skin fibroblast cells (Fig. 4) . At 1 ng/ml, IL-4 caused a modest stimulation of growth of both fibroblast cell lines and this growth stimulation was statistically significant compared to that of control untreated cells (P < 0.001). Similarly, the stimulation of normal HUVE cells and human adrenal capillary endothelial (HACE) cells have previously been reported (11) . In contrast, IL-4 caused the inhibition of PM-RCC tumor cell growth in a dosedependent manner (Fig. 4) . These data further indicate the significance of our observations and confirm cell type-specific effects of IL-4 on growth inhibition. Regulation of IL-4R by IL-4. To understand the mechanism of inhibition of tumor cell growth by IL-4, we investigated the regulation of IL-4R by IL-4. PM-RCC cells were cultured with or without IL-4 (20 ng/ml) for a 4-72-h period. Cells were then harvested using versene and the expression of IL-4R and its affinity were determined by equilibrium binding and Scatchard plot analysis. IL-4 significantly downregulated its receptors after 4 h of incubation (data not shown) and this down regulation was optimal after 72 h of incubation. '25IL-4 specifically bound to RCC tumor cells in a concentration-dependent manner but this binding was significantly decreased after 72-h treatment with IL-4 ( Fig. 5 A) . Scatchard plot analysis of the binding data revealed that the density of IL-4 receptors was decreased from 2,957±703 (n = 2) IL-4R molecules/ cell on untreated cells to 1,298±645 (n = 2) IL-4R molecules/ cell on treated cells (Fig. 5 B) . However, the dissociation constant in IL-4 treated cells (98±19 pM) was similar to that of untreated cells (94±14 pM).
Discussion
In this study, we demonstrate that RCC tumor cells express high affinity IL-4R. The expression of high affinity IL-4R on human RCC tumor cells has not been previously reported. Our results demonstrate the expression of IL-4R at the protein and gene level. The IL-4R appear to be functional as IL-4 was able to inhibit RCC tumor cell growth in vitro. A neut body to IL-4 was able to abrogate the growth inhi of IL-4.
The role of IL-4R on hurhan RCC tumor known. IL-4R may have some regulatory role i growth in vivo. Previous studies have suggested th;
be associated with an oncogene or may itself be a gene (26) . However, these possibilities are unlikel3 studies and those of others (I17, 18) show that IL-4 liferative effects on tumor cells.
Recently, IL-4 has also been shown to inhibit the growth of human hematopoietic cell derived tumors such as multiple myng/ml) eloma, lymphoma (27) , and chronic myelomonocytic leuke--_0 mia cells (28) . Moreover, IL-4 increased the antiproliferative effects mediated by tumor necrosis factor on various human tumor lines including breast carcinoma, epidermoid carcinoma, and histiocytic lymphoma cells (29) . Thus our data agree with published reports on growth inhibitory function of IL-4.
Interestingly, in contrast to the inhibition of RCC tumor cell growth, IL-4 did not inhibit the growth of control Molt-4 and Daudi lymphoblastoid cell lines (Fig. 3) . Molt-4 cells did not express IL-4R at the mRNA level or on the cell surface consistent with the lack of IL-4 effect on these cells. However, Daudi cells did express IL-4R mRNA but expressed a lower number of IL-4R on cell surface (< 100 molecules bound/cell) (Table I ) compared to RCC tumor cells ( Fig. 1) . Daudi cell lines have been shown to express varying number of IL-4R, however, receptor numbers observed in our studies were lower than those observed previously (19, 25) . Difference in cell lines may explain this difference. Thus lower numbers of IL-4R present on Daudi cells might explain the lack of IL-4 effect on these cells.
The mechanism for IL-4 unresponsiveness on Daudi and Molt-4 cells based on receptor number/cell cannot be explained in the light ofdata obtained with normal cells. Normal fibroblast and endothelial cells expressed a higher number of IL-4 receptors than Daudi cells, however, in contrast to data observed on RCC tumor cells, IL-4 caused a modest growth stimulation of normal cells. These data are in agreement with a published report in which IL-4 has been shown to be a mitogen for normal HUVE and human adrenal capillary endothelial cell lines (1 1). IL-4 has also been shown to be a growth factor for murine normal fibroblast cell lines (30) , however, its effects on the growth of normal human fibroblast cells has not been reported. We observed a modest but significant growth-stimulatory effect of low concentration of IL-4 on two human normal fibroblast cell lines (Fig. 4) .
We considered that the difference in receptor affinities may M00 3000 account for differences in IL-4 response in various cell types.
However, we have found that the Kd was not different on norvelil) mal, lymphoblastoid, and RCC tumor cells. These different cells. Tumor cell types might differ in the mechanisms of receptor internal-) ng/ml) for ization, processing, and/or signal transduction triggered by ILto remove ex-4 binding to its receptors. Irrespective of the mechanism of IL-4 for 2 h action, our data suggest that IL-4 may be a useful agent for the inlabeled IL-4 regulation of RCC tumor growth in vivo without mounting nber of spe-inhibitory effects on normal cells. and used to Our data also demonstrate that IL-4 can downregulate its At shown in -d in duplicate own receptors. Transient downregulation of IL-4R by IL-4 on human Jijoye cell line has been previously reported (31) . However, on resting T and B lymphocytes IL-4 has been shown to tralizing anti-upregulate its receptors (32) . The significance of downregulaibitory effects tion ofIL-4R by IL-4 on human RCC tumor cells remains to be determined. It is possible that the downregulation of IL-4R cells is not may be involved in the mechanism of inhibition of tumor in tumor cell growth by IL-4. at IL-4R may IL-4 has also been shown to upregulate classes I and II HLA X novel onco-antigens on some tumor cells including RCC cells (17, 18) . In y because our murine studies perilymphatic administration of low doses of I has antipro-IL-4 has been shown to cause the rejection of established tumors by host immune cells (14) . Furthermore, murine tumor cells transduced with IL-4 gene can abrogate the growth of tumor cells in vivo (15) or cause the regression of established tumor at a distant site due to enhanced tumor immunogenicity and enhancement of CTL response (16). These findings, particularly, in a murine experimental model for RCC using IL-4 transduced Renca tumor cells (16), reinforce the importance of our data demonstrating the expression of functional IL-4R on human RCC tumor cells. Taken together, these observations can help develop strategies for the treatment of human RCC in which IL-4R may be used as a target for IL-4 itself, IL-4 toxin therapy, or, alternatively, in gene therapy (16).
